Equillium, Inc.
NASDAQ:EQBiotechnology
+$0.05 today
- Market cap
- $90.56M
- Beta
- 1.76
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.20
Volume 0.89M
Average 0.60M
EQ Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Equillium, Inc.NASDAQ: EQ
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $24K fell 27.3% year over year, behind the -22.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 4.3% from the prior quarter. Over 3 fiscal years it compounded at -0.6% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -27.3% toward the trailing-twelve-month pace of -22.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 116K USD
- Year-over-year change
- -15.3%
- 4-year CAGR
- +12.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 116K | -15.3% |
| FY2024 | 2024-12-31 | 137K | +8.7% |
| FY2023 | 2023-12-31 | 126K | +6.8% |
| FY2022 | 2022-12-31 | 118K | +63.9% |
| FY2021 | 2021-12-31 | 72K | — |
Depreciation & Amortization vs competitors
How EQ compares with its peers on the latest reported figures
- EQ's LTM Mar 2026 depreciation & amortization of $107K is the 9th highest of the 10 companies compared; the peer median is $487.33K.
- Its year-over-year change of -22.5% is the 8th highest of 10, against a peer median of +6.7%.
- Over three fiscal years its annual growth of -0.6% compares with a peer median of +11.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.88M | -3.1% | +15.8% | — | |
| LTM Mar 2026 | $5.17M | -29.3% | -20.7% | 7.8% | |
| LTM Mar 2026 | $3.01M | +10.5% | +24.4% | 9.2% | |
| LTM Mar 2026 | $1.17M | +6.7% | +6.9% | 82.6% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $487.33K | +42.9% | +666.9% | — |
| LTM Mar 2026 | $306K | +6020.0% | +229.4% | 13.3% | |
| LTM Mar 2026 | $267K | +621.6% | -34.3% | — | |
| LTM Mar 2026 | $119.64K | +3.7% | -17.0% | 35.9% | |
| LTM Mar 2026 | $107K | -22.5% | -0.6% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding EQ) | $487.33K | +6.7% | +11.3% | 13.3% | |
Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15.76M | 36.08M | 41.1M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 116K |
| Gross Profit | 0 | 15.76M | 36.08M | 41.1M | (116K) |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | — |
| Research & Development | 26.38M | 37.55M | 37.04M | 37.43M | 12.84M |
| Selling, General & Admin | 11.41M | 17.24M | 13.57M | 11.94M | 10.79M |
| Operating Expenses | 37.79M | 77.84M | 50.61M | 49.36M | 23.63M |
| Depreciation & Amortization | 72K | 118K | 126K | 137K | 116K |
| EBITDA | (37.91M) | (61.26M) | (12.14M) | (7.57M) | (22.28M) |
| EBITDA Margin | — | -388.7% | -33.6% | -18.4% | — |
| Operating Income | (37.79M) | (62.08M) | (14.52M) | (8.27M) | (23.63M) |
| Operating Margin | — | -393.9% | -40.2% | -20.1% | — |
| Interest Income | 57K | 420K | 2.33M | 1.38M | 833K |
| Interest Expense | 1.07M | 1.05M | 491K | 0 | 0 |
| Other Income / Expenses | (1.27M) | (352K) | 1.77M | 563K | 1.24M |
| Income Before Tax | (39.05M) | (62.43M) | (12.76M) | (7.71M) | (22.4M) |
| Pre-Tax Margin | — | -396.1% | -35.3% | -18.8% | — |
| Income Tax Expense | 0 | 0 | 580K | 361K | 0 |
| Net Income | (38.98M) | (62.43M) | (13.34M) | (8.07M) | (22.4M) |
| Net Margin | — | -396.1% | -37.0% | -19.6% | — |
| EPS (Basic) | (1.35) | (3.19) | (0.38) | (0.23) | (0.39) |
| EPS (Diluted) | (1.35) | (3.19) | (0.38) | (0.23) | (0.39) |
| Weighted Avg Shares | 28.81M | 33.73M | 34.73M | 35.36M | 91.88M |
| Weighted Avg Shares (Diluted) | 28.81M | 33.73M | 34.73M | 35.36M | 91.88M |
Equillium, Inc.
NASDAQ:EQ
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.